CSPC Pharmaceutical Group (HKG:1093) SYS6010 met the pre-specified primary endpoint of progression-free survival as reviewed by the Independent Data Monitoring Committee.
The endpoint was reached in a phase III trial testing the product as a monotherapy versus platinum-based chemotherapy for non-small cell lung cancer, according to a Wednesday Hong Kong bourse filing.
According to the results, the drug candidate's progression-free survival was significantly superior to existing treatment regimens, with high efficacy and favorable safety profile.